These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3778526)

  • 21. Semiquinone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese hamster ovary cells.
    Malisza KL; McIntosh AR; Sveinson SE; Hasinoff BB
    Free Radic Res; 1996 Jan; 24(1):9-18. PubMed ID: 8747888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of S9788, cyclosporin A and verapamil on intracellular accumulation of doxorubicin, daunorubicin and daunorubicinol in primary rat hepatocyte culture].
    Le Bot MA; Kernaleguen D; Simon I; Berlion M; Riché C
    Ann Biol Clin (Paris); 1996; 54(1):21-4. PubMed ID: 8731791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.
    Gessner T; Preisler HD; Azarnia N; Bolanowska W; Vogler WR; Grunwald H; Joyce R; Goldberg J
    Med Oncol Tumor Pharmacother; 1987; 4(1):23-31. PubMed ID: 3600054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
    Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species.
    Yesair DW; Schwartzbach E; Shuck D; Denine EP; Asbell MA
    Cancer Res; 1972 Jun; 32(6):1177-83. PubMed ID: 5030818
    [No Abstract]   [Full Text] [Related]  

  • 26. Anthracycline antibiotic reduction by spinach ferredoxin-NADP+ reductase and ferredoxin.
    Fisher J; Abdella BR; McLane KE
    Biochemistry; 1985 Jul; 24(14):3562-71. PubMed ID: 3862429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats.
    Catapano CV; Guaitani A; Broggini M; Corada M; Bartosek I; Italia C; Donelli MG
    Anticancer Res; 1988; 8(4):725-31. PubMed ID: 3178163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracycline antibiotic pharmacology and metabolism.
    Bachur NR
    Cancer Treat Rep; 1979 May; 63(5):817-20. PubMed ID: 455323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol.
    Olson RD; Li X; Palade P; Shadle SE; Mushlin PS; Gambliel HA; Fill M; Boucek RJ; Cusack BJ
    Toxicol Appl Pharmacol; 2000 Dec; 169(2):168-76. PubMed ID: 11097869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.
    Londos-Gagliardi D; Baurain R; Robert J; Aubel-Sadron G
    Cancer Chemother Pharmacol; 1982; 9(1):45-8. PubMed ID: 6958392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular pharmacology of amino acid derivatives of daunorubicin and doxorubicin in suspension of renal proximal tubules.
    Hjelle JT; Baurain R; Masquelier M; Trouet A
    J Pharmacol Exp Ther; 1984 May; 229(2):372-80. PubMed ID: 6585548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.
    Hintzpeter J; Seliger JM; Hofman J; Martin HJ; Wsol V; Maser E
    Toxicol Appl Pharmacol; 2016 Feb; 293():21-9. PubMed ID: 26773812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells.
    Gessner T; Vaughan LA; Beehler BC; Bartels CJ; Baker RM
    Cancer Res; 1990 Jul; 50(13):3921-7. PubMed ID: 2112982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daunorubicin metabolism: estimation of daunorubicin reductase.
    Bachur NR; Huffman DH
    Br J Pharmacol; 1971 Dec; 43(4):828-33. PubMed ID: 5152029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
    Ferguson DC; Cheng Q; Blanco JG
    Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.
    Hulhoven R
    Biomedicine; 1978 Jul; 29(5):164-7. PubMed ID: 719130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daunorubicin metabolism by rat tissue preparations.
    Bachur NR; Gee M
    J Pharmacol Exp Ther; 1971 Jun; 177(3):567-72. PubMed ID: 4398190
    [No Abstract]   [Full Text] [Related]  

  • 40. Rat heart anthracycline-binding polypeptides identified by photoaffinity labeling.
    Felsted RL; Glover CJ; Clawson RE; Averbuch SD
    Mol Pharmacol; 1986 Oct; 30(4):388-97. PubMed ID: 3463845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.